ProPhase Labs, Inc. Accrued Liabilities, Current
ProPhase Labs, Inc. (PRPH) had Accrued Liabilities, Current of $1.89 million as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-06-01
- 2025-12-31: Accrued Liabilities, Current $1.89M.
- 2024-12-31: Accrued Liabilities, Current $1.95M.
- 2023-12-31: Accrued Liabilities, Current $1.42M; Accrued Liabilities, Current as first filed $1.45M.
- 2022-12-31: Accrued Liabilities, Current $714.00K.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2025-12-31 | $1.89M 10-K · filed 2026-06-01 | |
| 2024-12-31 | $1.95M 10-K · filed 2026-06-01 | |
| 2023-12-31 | $1.42M 10-K · filed 2025-04-01 | $1.45M 10-K · filed 2024-03-29 |
| 2022-12-31 | $714.00K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $328.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $226.00K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $356.00K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $300.00K 10-K · filed 2023-03-29 | |
| 2021-09-30 | $251.00K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $467.00K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $305.00K 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $304.00K 10-K · filed 2022-03-31 | |
| 2020-09-30 | $548.00K 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $158.00K 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $122.00K 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $218.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $87.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $123.00K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $108.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $167.00K 10-K · filed 2020-03-26 | |
| 2018-09-30 | $117.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $76.00K 10-Q · filed 2018-08-20 | |
| 2018-03-31 | $84.00K 10-Q/A · filed 2018-08-20 | $78.00K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $66.00K 10-K · filed 2019-03-26 | $48.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |